Study of IDO Inhibitor in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer
Status:
Completed
Trial end date:
2018-10-17
Target enrollment:
Participant gender:
Summary
This phase I/II trial is designed to efficiently identify the regimen limiting toxicity (RLT)
and recommended phase 2 dose (RP2D) for the combination of the immunotherapeutic agent
indoximod when administered in combination with standard of care chemotherapy gemcitabine
plus nab-paclitaxel in subjects with metastatic adenocarcinoma of the pancreas. All subjects
will receive the same standard gemcitabine plus nab-paclitaxel regimen, plus indoximod in
doses increasing from 600 mg twice daily to, potentially, 1200 mg twice daily.